Methylprednisolone Sodium Succinate for Injection

The main ingredient of this product is methylprednisolone sodium succinate. Each 1ml double chamber bottle contains diluent (9mg benzyl alcohol and water for injection) in the upper chamber, and methylprednisolone sodium succinate and excipients in the lower chamber: sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate (anhydrous), lactose, 10% sodium hydroxide solution and water for injection.

Unless used as a replacement for certain endocrine diseases, glucocorticoids are only a symptomatic treatment. 1. Used for the following treatments: (1) Anti-inflammatory treatment of rheumatic diseases as a short-term auxiliary drug (to help patients get through the acute or critical period), used for: post-traumatic osteoarthritis. Synovitis caused by osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (individual patients may need low-dose maintenance treatment). Acute or subacute bursitis. Epicondylar inflammation. Acute nonspecific synovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. For other details, please refer to the instructions.

Follow doctor's advice

1. Systemic side effects may be observed. Although they rarely occur during short-term treatment, they should still be followed up carefully. This is part of the follow-up of steroid treatment and is not specific to a particular drug. (1) Possible adverse reactions of glucocorticoids (such as methylprednisolone) are: fluid and electrolyte disorders. Compared with cortisone and hydrocortisone, synthetic derivatives (such as methylprednisolone) are less likely to have mineralocorticoid effects. A sodium-restricted, potassium-supplemented diet may be necessary. All corticosteroids increase the loss of calcium ions. Sodium retention. Fluid retention. For more details, please refer to the instructions.

1. Systemic fungal infection. 2. Allergic to methylprednisolone sodium succinate or excipients. 3. Relative contraindications 4. Special risk groups: 5. Patients belonging to the following special risk groups should be closely monitored and the course of treatment should be shortened as much as possible (see also

Precautions during pregnancy and lactation: 1. The results of a multicenter study showed that this product should not be routinely used to treat craniocerebral injury. In this study, the mortality rate of patients in the methylprednisolone sodium succinate group was higher than that in the placebo group 2 weeks after injury (relative risk 1.18). However, the causal relationship between the increase in mortality and the treatment of this product has not been established. 2. Special risk groups Patients belonging to the following special risk groups should be closely monitored and the course of treatment should be shortened as much as possible. For other details, please refer to the instructions.

Beneficial interactions: 1. Prevent nausea and vomiting caused by tumor chemotherapy; 2. Chemotherapy regimens for mild to moderate vomiting: Chlorinated phenothiazines can be used in combination with the first dose of methylprednisolone (1 hour before chemotherapy) to enhance the effect. 3. Chemotherapy regimens for severe vomiting: Metoclopramide or butyrophenone drugs can be used in combination with the first dose of methylprednisolone (1 hour before chemotherapy) to enhance the effect. For other details, please refer to the instructions.

cool

40mg